Rapamycin in islet transplantation: Friend or foe?

Thierry Berney, Antonio Secchi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.

Original languageEnglish
Pages (from-to)153-161
Number of pages9
JournalTransplant International
Volume22
Issue number2
DOIs
Publication statusPublished - Feb 2009

Fingerprint

Islets of Langerhans Transplantation
Sirolimus
Immunosuppressive Agents
Islets of Langerhans
Immunosuppression
Publications
Regeneration
History
Transplants
Survival
Pharmaceutical Preparations

Keywords

  • Islet function
  • Islet transplantation
  • Rapamycin
  • Sirolimus
  • Toxicity

ASJC Scopus subject areas

  • Transplantation

Cite this

Rapamycin in islet transplantation : Friend or foe? / Berney, Thierry; Secchi, Antonio.

In: Transplant International, Vol. 22, No. 2, 02.2009, p. 153-161.

Research output: Contribution to journalArticle

Berney, Thierry ; Secchi, Antonio. / Rapamycin in islet transplantation : Friend or foe?. In: Transplant International. 2009 ; Vol. 22, No. 2. pp. 153-161.
@article{8408ebbd797c4b4db75e245a50ff24fb,
title = "Rapamycin in islet transplantation: Friend or foe?",
abstract = "The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.",
keywords = "Islet function, Islet transplantation, Rapamycin, Sirolimus, Toxicity",
author = "Thierry Berney and Antonio Secchi",
year = "2009",
month = "2",
doi = "10.1111/j.1432-2277.2008.00743.x",
language = "English",
volume = "22",
pages = "153--161",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Rapamycin in islet transplantation

T2 - Friend or foe?

AU - Berney, Thierry

AU - Secchi, Antonio

PY - 2009/2

Y1 - 2009/2

N2 - The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.

AB - The Edmonton protocol was undoubtedly a major step forward in the history of islet transplantation. Its immunosuppression regimen was largely based on the mTOR inhibitor rapamycin (sirolimus), which remains the most frequently used immunosuppressive drug in clinical islet transplant protocols. As time reveals the somewhat disappointing long-term results achieved with the Edmonton protocol, a number of publications have appeared addressing the potential beneficial or deleterious role of rapamycin on islet cell engraftment, function survival and regeneration, as well as on its side-effects in human subjects. This paper reviews the sometimes contradictory evidence on the impact of rapamycin in islet transplantation.

KW - Islet function

KW - Islet transplantation

KW - Rapamycin

KW - Sirolimus

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=58149310853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149310853&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2008.00743.x

DO - 10.1111/j.1432-2277.2008.00743.x

M3 - Article

C2 - 18713146

AN - SCOPUS:58149310853

VL - 22

SP - 153

EP - 161

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 2

ER -